

1994, which issued as patent 5,631,224 on October 28, 1998, and is now reissued as reissue patent RE 37,302 on July 31, 2001, which is a 371 national application of PCT/DK93/00099 filed on March 18, 1993, which claims priority to Danish application 363/92 filed March 19, 1992, the contents of which are fully incorporated herein by reference. - -

IN THE CLAIMS:

Please cancel claims 9-14 without prejudice.

Please add the following claims:

15. (New) A method for treating type 2 diabetes, said method comprising administering to a patient in need of said treatment an effective amount of metformin and an effective amount of a GLP-1 related peptide, where said GLP-1 related peptide is GLP-1 (7-37), GLP-1 (7-36) amide, an analogue of GLP-1 (7-37) or GLP-1 (7-36) amide, or a functional derivative thereof.

16. (New) The method of claim 15, wherein said GLP-1 related peptide is GLP-1 (7-36) amide.

17. (New) The method of claim 15, wherein said GLP-1 related peptide is an analogue of GLP-1 (7-37).

18. (New) The method of claim 17, wherein said analogue of GLP-1 (7-37) has one amino acid of GLP-1 (7-37) exchanged by another amino acid.

19. (New) The method of claim 15, wherein said GLP-1 related peptide is a functional derivative of an analogue of GLP-1 (7-37).

20. (New) The method of claim 19, wherein said analogue of GLP-1 (7-37) has one amino acid of GLP-1(7-37) exchanged by another amino acid.

REMARKS

Claims 9-14 have been canceled without prejudice or disclaimer. Therefore, claims 15-20 are pending in the present application. Support for added claims 15-20 is found in the application *inter alia* at page 6, lines 28-34 and at page 7, lines 7-14.

As requested by the Examiner, the title of the invention has been amended to more accurately define the claimed invention and the specification has been amended to recite the status of nonprovisional applications to which priority is claimed.